Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease

Sponsor
Synergic Medical Technologies, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05830110
Collaborator
(none)
30
1
2
66
0.5

Study Details

Study Description

Brief Summary

The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses a novel stimulation pattern to disrupt the pathophysiological mechanism that is responsible for PD symptoms and thus restore motor function.

Condition or Disease Intervention/Treatment Phase
  • Device: Active Vibrotactile Coordinated Reset
  • Device: Sham vibrotactile coordinated reset
N/A

Detailed Description

Up to thirty adults with bilateral, moderate stage idiopathic PD will be enrolled in this longitudinal study. Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals. This longitudinal protocol will be open-ended to enable continued treatment to those interested / motivated.

Study treatment will consist of daily, four-hour vibrotactile Coordinated Reset (vCR) stimulation sessions on a continual basis. All daily vCR stimulation sessions will occur at the participant's home (ON-medication) and can be broken up into two, two-hour blocks (with no more than 12 hours between stimulation blocks) to be less cumbersome and better integrate into the participant's daily life. Daily home-based treatment will be unsupervised, though timely support is guaranteed by Synergic Medical Technologies (SMT) support staff when needed (e.g., when usability or IT issues arise). Daily stimulation / device usage will be automatically logged by the device and continuously monitored by SMT staff, meanwhile participants will keep a med diary so we can monitor their med usage (and how it relates to extended exposure) over time. Participants will be able to transition to an as-needed basis with treatment after four months and once they are familiar with the treatment and their body's response to it, to better alleviate PD symptoms.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals.Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals.
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
Actual Study Start Date :
Jun 1, 2019
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active vibrotactile coordinated reset

mechanical vibrotactile stimulation to the fingers in a defined pattern

Device: Active Vibrotactile Coordinated Reset
Gloves providing vibrotactile coordinated reset stimulation

Sham Comparator: Sham vibrotactile coordinated reset

mechanical vibrotactile stimulation to the fingers in a defined pattern

Device: Sham vibrotactile coordinated reset
Gloves providing sham vibrotactile coordinated reset stimulation

Outcome Measures

Primary Outcome Measures

  1. Movement Disorder Society - Change in Universal Parkinson Disease Rating Scale (MDS-UPDRS) [baseline, 2 months, 4 months]

    Change in MDS-UPDRS score using Part 3 of the scale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • between the ages 45 and 90

  • diagnosis of bilateral, moderate stage idiopathic PD

  • qualify for EEG procedures

Exclusion Criteria:
  • on dopamine agonist medications and exhibiting compulsive behaviors

Contacts and Locations

Locations

Site City State Country Postal Code
1 Synergic Medical Technologies Eugene Oregon United States 97403

Sponsors and Collaborators

  • Synergic Medical Technologies, Inc.

Investigators

  • Principal Investigator: Phan Luu, PhD, Synergic Medical Technologies, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Synergic Medical Technologies, Inc.
ClinicalTrials.gov Identifier:
NCT05830110
Other Study ID Numbers:
  • VCR-Longitudinal
First Posted:
Apr 26, 2023
Last Update Posted:
Apr 26, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Synergic Medical Technologies, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 26, 2023